Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; silicon dioxide; povidone; purified talc; magnesium stearate; hypromellose; titanium dioxide; macrogol 400; iron oxide yellow - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; silicon dioxide; povidone; purified talc; magnesium stearate; hypromellose; titanium dioxide; macrogol 400; indigo carmine - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - pantoprazole sodium sesquihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 41.412 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; crospovidone; povidone; ethylcellulose; purified talc; iron oxide red; light magnesium oxide; diethyl phthalate; titanium dioxide; magnesium stearate; silicified microcrystalline cellulose; hypromellose; copovidone; sodium lauryl sulfate; macrogol 8000; colloidal anhydrous silica; methacrylic acid - ethyl acrylate copolymer (1:1); lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 41.412 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: hypromellose; magnesium stearate; copovidone; methacrylic acid - ethyl acrylate copolymer (1:1); ethylcellulose; light magnesium oxide; povidone; iron oxide red; polysorbate 80; silicified microcrystalline cellulose; colloidal anhydrous silica; sodium lauryl sulfate; macrogol 8000; purified talc; diethyl phthalate; crospovidone; titanium dioxide; lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 41.412 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: crospovidone; macrogol 8000; methacrylic acid - ethyl acrylate copolymer (1:1); diethyl phthalate; povidone; silicified microcrystalline cellulose; titanium dioxide; polysorbate 80; hypromellose; purified talc; iron oxide red; ethylcellulose; colloidal anhydrous silica; light magnesium oxide; sodium lauryl sulfate; copovidone; magnesium stearate; lactose monohydrate; maize starch; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 41.412 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: copovidone; silicified microcrystalline cellulose; titanium dioxide; sodium lauryl sulfate; iron oxide red; polysorbate 80; magnesium stearate; macrogol 8000; ethylcellulose; light magnesium oxide; povidone; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; diethyl phthalate; purified talc; colloidal anhydrous silica; lactose monohydrate; maize starch; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - esomeprazole magnesium, quantity: 41.412 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide red; sodium lauryl sulfate; povidone; ethylcellulose; purified talc; magnesium stearate; macrogol 8000; light magnesium oxide; hypromellose; titanium dioxide; polysorbate 80; copovidone; silicified microcrystalline cellulose; crospovidone; colloidal anhydrous silica; diethyl phthalate; lactose monohydrate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; sucrose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer